Rocket Pharmaceuticals (RCKT) Current Assets (2014 - 2026)
Rocket Pharmaceuticals (RCKT) posted Current Assets of $149.8 million for Q1 2026, down 22.26% sequentially from $192.7 million in Q4 2025, and down 53.83% YoY from $324.5 million in Q1 2025.
Rocket Pharmaceuticals (RCKT) Current Assets (2014 - 2026) Analysis & Trends
Rocket Pharmaceuticals has reported Current Assets for 13 years, with the latest figure at $149.8 million in Q1 2026.
- Quarterly Current Assets fell 53.83% year-over-year to $149.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $149.8 million (down 53.83% YoY) and the FY2025 annual result came in at $192.7 million, down 49.04% from the prior year.
- Current Assets declined to $149.8 million in Q1 2026 per RCKT's latest filing, from $192.7 million in the prior quarter.
- Over five years, Current Assets peaked at $446.9 million in Q3 2023 and troughed at $149.8 million in Q1 2026.
- A 5-year average of $309.4 million and a median of $324.5 million in 2025 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2026: Current Assets surged 43.63% in 2023, then plunged 53.83% in 2026.
- Over 5 years, Current Assets stood at $364.1 million in 2022, then grew by 3.89% to $378.2 million in 2023, then declined by 0.01% to $378.2 million in 2024, then slumped by 49.04% to $192.7 million in 2025, then slipped by 22.26% to $149.8 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $149.8 million, $192.7 million, and $227.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Rocket Pharmaceuticals | 380.92 Mn | 380.92 Mn | - | 289.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 289.55 Mn |
| Mar 31, 2026 | 149.83 Mn |
| Dec 31, 2025 | 192.73 Mn |
| Sep 30, 2025 | 227.68 Mn |
| Jun 30, 2025 | 277.16 Mn |
| Mar 31, 2025 | 324.49 Mn |
| Dec 31, 2024 | 378.18 Mn |
| Sep 30, 2024 | 241.75 Mn |
| Jun 30, 2024 | 292.73 Mn |
| Mar 31, 2024 | 345.16 Mn |
| Dec 31, 2023 | 378.22 Mn |
| Sep 30, 2023 | 446.87 Mn |
| Jun 30, 2023 | 312.07 Mn |
| Mar 31, 2023 | 338.03 Mn |
| Dec 31, 2022 | 364.06 Mn |
| Sep 30, 2022 | 311.13 Mn |
| Jun 30, 2022 | 325.77 Mn |
| Mar 31, 2022 | 353.85 Mn |
| Dec 31, 2021 | 392.06 Mn |
| Sep 30, 2021 | 425.07 Mn |